| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C09K2211-1011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C09K2211-1007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C09K2211-1029
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C09K2211-1088 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0021
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C09K11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-252
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H1-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H15-252
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C09K11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H1-00 |
| filingDate |
2021-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2022-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-113173955-B |
| titleOfInvention |
A two-photon therapeutic prodrug targeting Golgi pH response and its preparation |
| abstract |
The invention discloses a two-photon diagnosis and treatment prodrug targeting the pH response of the Golgi body and a preparation method thereof. The structure of the diagnosis and treatment prodrug compound is shown in formula I. The prodrug molecule sensitively triggers the cleavage reaction through abnormal pH changes when tumor cells are acidified in the Golgi due to the lack of transmembrane protein 165, which not only activates the fluorophore to generate two-photon fluorescence in cell imaging, but also releases the Active doxorubicin is used in cancer treatment. The advantage is that pH-activated prodrugs provide a new platform for in vivo cancer diagnosis and Golgi-targeted anticancer chemotherapy, and are successfully applied to track drug release in vivo and treat xenograft tumor mouse models. |
| priorityDate |
2021-03-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |